Revenue segments as reported by the company.

Protein Sciences

Diagnostics and Genomics

lntersegment

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Bio-Techne Corp reports steady Q3 revenue growth amidst China challenges

Bio-Techne Corp reported steady Q3 revenue growth despite challenges in China and temporary headwinds. The company is focused on driving growth in strategic platforms and expanding key franchises. Succession planning and margin improvement are key areas of focus for future growth.

Bio-Techne reports strong Q2 earnings, eyes growth in diagnostics

Bio-Techne's Q2 2023 earnings call highlighted solid performance, strategic strengths in key segments, challenges in ordering patterns, and growth opportunities in diagnostics and research.
The company's focus on innovation, cost management, and strategic investments positions it well for future growth and reaching ambitious revenue targets by FY 2026.
Despite short-term challenges in certain markets, Bio-Techne remains optimistic about its long-term growth prospects and transparent communication with investors.
With a strong financial performance, expanding product portfolio, and a focus on high-growth areas, Bio-Techne is poised for sustained success and market leadership.

Bio-Techne reports solid Q3 performance, eyes growth in key segments

Bio-Techne's Q3 performance showcased strengths in key segments like ExoDx Prostate test demand and GMP proteins, despite challenges in certain markets and OEM destocking dynamics. The company's strategic focus on expanding the Wilson Wolf franchise and driving growth in ACD and key segments like cell and gene therapy position it well for future success. Addressing challenges and capitalizing on growth opportunities will be pivotal for Bio-Techne's continued expansion and market leadership.

Bio-Techne (TECH) excels in Q4, eyes growth amid challenges

Bio-Techne (TECH) reports strong revenue growth and promising future prospects.
Strategic focus on key segments like cell and gene therapy and spatial biology.
Challenges in macroenvironment and funding uncertainties require cautious navigation.
Active M&A strategy and investments to drive growth and market dominance.

Bio-Techne reports steady Q1 growth amid industry challenges

Bio-Techne's Q1 performance showed resilience amidst industry challenges, with a focus on key growth areas and regions. While facing headwinds, the company remains cautiously optimistic about future prospects, emphasizing long-term growth opportunities and productivity measures.

Bio-Techne reports Q2 revenue growth amidst China challenges and opportunities

Bio-Techne's Q2 performance reflects revenue growth and operational efficiency, despite challenges.
Strengths lie in core businesses, Diagnostics and Genomics growth, and record consumables usage in China.
Challenges include market declines, funding constraints, and headwinds in biopharma and academic markets.
Opportunities exist in market normalization, China growth, new product releases, and M&A strategies.

Bio-Techne surpasses Q3 expectations, eyes growth in emerging markets

Bio-Techne's Q3 showcased strong financial performance, with revenue growth and margin expansion across key segments, setting the stage for continued success.
The company's focus on innovation, awards recognition, and strategic market positioning in high-growth areas like cell and gene therapy underpin its competitive strength.
While facing challenges in certain regions and production constraints, Bio-Techne's proactive approach to scaling up manufacturing and diversifying markets positions it well for future growth.
With a clear emphasis on operational efficiency, market expansion, and strategic investments, Bio-Techne is poised for sustained success and value creation for stakeholders.

Bio-Techne reports solid Q4 performance and eyes market recovery

Bio-Techne's Q4 2024 performance reflects resilience and potential for accelerated growth as markets recover in fiscal year 2025.
Strategic leadership additions, productivity initiatives, and market recovery expectations position the company for future success.
Challenges such as capacity constraints and funding environments require strategic management for sustained growth.
Opportunities lie in market recovery, margin improvement, and growth prospects across different segments for Bio-Techne in the coming year.

Bio-Techne reports solid Q1 earnings, eyes growth in biotech markets

Bio-Techne (TECH) delivered solid Q1 2025 results with organic revenue growth, strong segment performances, and a focus on sustainability and strategic partnerships.
While facing challenges in certain markets, the company's emphasis on cost containment and productivity optimization bodes well for future profitability and resilience.
With a positive outlook for growth and opportunities in key segments, Bio-Techne is poised for continued success and market leadership in the biotech industry.
Investors can be optimistic about Bio-Techne's performance, strategic initiatives, and growth prospects, supported by a strong financial foundation and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

MINNEAPOLIS, Nov. 8, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene. The AmplideX® PCR/CE CFTR Kit, intended for research use only, provides broader coverage of the diverse U.S. population1,2 than any other commercially available, targeted CFTR testing assay.

Asuragen Launches New Kit to Enable Broader Coverage of Gene Variants Linked to Cystic Fibrosis

MINNEAPOLIS, Nov. 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present virtually at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, November 9, 2021 at 11:20 a.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne To Present At The Credit Suisse 30th Annual Healthcare Conference

MINNEAPOLIS, Nov. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the commercial availability of GMP-grade materials manufactured at  its St. Paul, MN GMP (Good Manufacturing Practices) manufacturing facility. The facility is dedicated to supporting large-scale production of GMP-grade proteins, including animal-free cytokines and growth factors, that are essential components of cell culture media for immuno-oncology, regenerative medicine and gene-modified cell therapy workflows.

Bio-Techne Announces Commercial Availability Of GMP-Grade Proteins From Dedicated GMP Facility

MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced inclusion in Inc.'s first annual Best-Led Companies list, an exciting 12-point measure of management excellence across the middle market — a select, data-driven list of the very strongest U.S. firms with revenue of $50 million to $2 billion. This novel program is the first Inc. recognition list to honor both public and private companies.

Bio-Techne Named in Inc.'s First-Annual Best-Led Companies

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q1 2022 Results - Earnings Call Transcript

Techne (TECH) delivered earnings and revenue surprises of 3.39% and 1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Q1 Earnings and Revenues Top Estimates

MINNEAPOLIS, Nov. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2021. First Quarter FY2022 Snapshot First quarter organic revenue increased by 21% (26% reported) to $257.7 million.

Bio-Techne Releases First Quarter Fiscal 2022 Results

Bio-Techne (NASDAQ:TECH) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement.

Bio-Techne's Earnings: A Preview

Fortinet

Alphabet

NVIDIA

Old Dominion Freight Line

In GuruFocus' High Quality Low CAPEX model portfolio, the companies with the biggest year-to-date returns are Fortinet Inc. ( FTNT , Financial), Nvidia Corp. ( NVDA , Financial), Old Dominion Freight Line Inc. ( ODFL , Financial), Alphabet Inc. ( GOOGL , Financial) and Bio-Techne Corp. ( TECH , Financial).

Top-Performing Stocks From the High Quality Low CAPEX Model Portfolio

MINNEAPOLIS, Oct. 13, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published important clinical research in the journal Prostate Cancer and Prostatic Diseases, entitled Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies . In this pooled analysis from three independent prospective-validation studies and more than 1200 subjects, principal investigator Dr. Erik Margolis, Chief of Urology at Englewood Hospital and Medical Center, and colleagues demonstrated the ExoDx Prostate test, or EPI, can discriminate high-grade (≥GG2) from low-grade (GG1) cancer and benign disease.

Bio-Techne Announces ExoDx Prostate Test Data Publication in the Journal of Prostate Cancer and Prostatic Diseases

MINNEAPOLIS, Oct. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 2, 2021, at 8:00 a.m. CDT to review first quarter 2022 financial results.

Bio-Techne To Host Conference Call On November 2, 2021 To Announce First Quarter 2022 Financial Results

MINNEAPOLIS, Sept. 14, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows.

Bio-Techne Launches ExCellerate™ iPSC Expansion Medium

MINNEAPOLIS and SALT LAKE CITY, Sept. 8, 2021 /PRNewswire/ -- Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, today announced a clinical research collaboration studying COVID-19 variants.

Bio-Techne And Carterra Initiate A Clinical Research Collaboration For COVID-19 Variant Analysis

Techne (TECH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Techne (TECH) Soars to 52-Week High, Time to Cash Out?

MINNEAPOLIS, Sept. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021 at 2:00 p.m.

Bio-Techne To Present At The 2021 Virtual Wells Fargo Healthcare Conference

Techne (TECH) possesses solid growth attributes, which could help it handily outperform the market.

Is Techne (TECH) a Solid Growth Stock? 3 Reasons to Think " Yes "

Mimecast

Option Care Health

NEW YORK, Aug. 24, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the opening of trading on Monday, August 30: S&P MidCap 400 constituent Bio-Techne Corp. (NASD:TECH) will replace Maxim Integrated Products Inc. (NASD:MXIM) in the S&P 500, S&P SmallCap 600 constituent Saia Inc. (NASD:SAIA) will replace Bio-Techne in the S&P MidCap 400, and BioLife Solutions Inc. (NASD:BLFS) will replace Saia in the S&P SmallCap 600. S&P 500 constituent Analog Devices Inc. (NASD:ADI) is acquiring Maxim Integrated Products in a deal pending final conditions.

Bio-Techne Set to Join S&P 500; Saia, Mimecast & Option Care Health to Join S&P MidCap 400; Others to Join S&P SmallCap 600

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Bio-Techne (TECH).

Can Bio-Techne (TECH) Stock Continue to Grow Earnings?

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q4 2021 Results - Earnings Call Transcript

Techne (TECH) delivered earnings and revenue surprises of 11.31% and 4.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Techne (TECH) Q4 Earnings and Revenues Beat Estimates

MINNEAPOLIS, Aug. 5, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2021. Fourth Quarter FY2021 Snapshot Fourth quarter organic revenue increased by 39% (47% reported) to $259.0 million.

Bio-Techne Releases Fourth Quarter Fiscal 2021 Results

MINNEAPOLIS, Aug. 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that scientists at the U.S. Centers for Disease Control and Prevention (CDC) recently highlighted the importance of fixed tissue analysis for retrospective diagnosis of SARS-CoV-2 infection and characterization of viral strains, particularly for fatal cases in which no previous testing for SARS-CoV-2 was performed. According to findings published in the March 2021 issue of the Journal of Infectious Disease, SARS-CoV-2 RNA was visualized directly in the autopsied tissues of suspected COVID-19 patients through in situ hybridization (ISH) using the RNAscope technology from Advanced Cell Diagnostics (ACD), a Bio-Techne brand.

Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2

MINNEAPOLIS, Aug. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host its 2021 Investor Day on Friday, September 10, 2021, starting at 9:00 a.m. EDT. The meeting will take place at the Lotte New York Palace Hotel, 455 Madison Avenue, New York City.

Bio-Techne Announces 2021 Investor Day and Webcast

MINNEAPOLIS, July 28, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and PROGEN today announced the launch of the Simple Plex™ Adeno-Associated Virus (AAV2) viral titer assay for AAV2 total capsid quantification.  Bio-Techne, owner of the leading ProteinSimple branded protein analysis portfolio of products, and PROGEN will offer the Simple Plex AAV2 viral titer assay on Ella™ instruments, its multiplexing immunoassay system.

Bio-Techne and PROGEN Introduce New Simple Plex AAV2 Immunoassay

MINNEAPOLIS, July 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope in situ hybridization technology portfolio with the release of new RNAscope HiPlex V2 assay for formalin-fixed paraffin-embedded (FFPE) and fixed and fresh frozen samples for up to 12 targets. RNAscope is a proven and well characterized technology, with over 4400 peer reviewed publications.

Bio-Techne Announces Commercial Release of RNAscope™ HiPlex V2 Assay for Single Cell Validation and Spatial Transcriptomic Profiling of Complex Tissues on FFPE, Fixed and Fresh Frozen Samples.

News for Bio-Techne Stock (TECH)